TCT 137: Contribution of plaque composition to the extent of plaque fracture and dissection following drug-coated balloon angioplasty in de novo small vessel disease: an interim report of the TRANSFORM-I trial

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of patients with any cardiovascular disease to include devices, drugs, and digital health care products listed below:

• Consultant Fee/Honoraria/Speaker's Bureau (Personal) - SMT; Philips; Novartis; Merillife
• Consultant Fee/Honoraria/Speaker's Bureau (Institutional) - Xeltis